Skip to main content

Ionis Pharmaceuticals Inc

IONS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000874015

In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 4 sales; 515 institutions reported holding it in 13F filings for Q2 2026, worth $14.3B in total; ARK Invest is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Ionis Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $1.06M in total
Open-market sells
4 filings
4 insiders, $3.55M in total
Insiders trading
5
Net value
−$2.49M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Ionis Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Ionis Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Bennett C FrankEVP, Chief Scientific Officer60,128Sep 2, 20268
O'Neil Patrick R.EVP CLO & General Counsel59,205Sep 2, 202610
Monia Brett PChief Executive Officer242,760Sep 2, 202610
Birchler BrianEVP, Corp and Development Ops102,883Sep 2, 20268
Hayden Michael RDirector24,000IndirectJul 31, 20262
Reikes Peter NDirector14,222Jul 17, 20262
Hantson LudwigDirector–Jul 17, 20262
Herman Joan EDirector51,306Jul 17, 20263
Berthelsen Spencer RDirector161,233Jul 17, 20264
Diaz Allene M.Director3,811Jul 9, 20263
Kordasiewicz Holly B.EVP, Chief Development Officer22,096Jul 9, 20264
Yang Michael J.Director7,940Jul 6, 20262
Loscalzo JosephDirector36,330Jul 6, 20264
Klein Joseph IIIDirector11,014Jul 6, 20265
Baroldi JosephEVP, Chief Business Officer4,669IndirectJun 30, 20269
Schneider EugeneEVP, Chf Clinical Develop Ofcr77,114Jun 30, 20265
Swayze EricEVP Research21,759Jun 26, 20269
Parshall B LynneDirector51,344Apr 17, 20263
Jenne KyleEVP, Chf GL Pdt Str Ofcr23,713Apr 17, 20264
Devers Shannon L.EVP, Chief Human Resources Ofc16,348Apr 2, 20268
Hougen Elizabeth LEVP, Finance & CFO82,660Mar 18, 20265
Wender Joseph HDirector36,035IndirectDec 3, 20254
Geary Richard SEVP, Chief Development Officer59,657Nov 7, 20253
Cadoret-Manier OnaizaEVP,Chf GL Pdt Str & Oper Ofc35,788Sep 4, 20240
Muto Frederick TDirector59,597Jul 19, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 19, 2021 (view filing)Jul 154 daysKlein Joseph IIIDirectorSSale−4.33K$35.30−$153.0K−19.3%18.1K after
Apr 5, 2022 (view filing)Apr 14 daysMonia Brett PChief Executive OfficerSSale−355$37.49−$13.3K−0.4%88.7K after
Apr 14, 2022 (view filing)Apr 122 daysO'Neil Patrick R.EVP CLO & General CounselSSale−6.79K$40.06−$272.1K−16.4%34.5K after
Apr 25, 2022 (view filing)Apr 214 daysSwayze EricEVP ResearchSSale−378$44.15−$16.7K−1.8%20.4K after
Jul 19, 2022 (view filing)Jul 154 daysKlein Joseph IIIDirectorSSale−1.33K$38.24−$51.0K−6.6%18.8K after2 lots
Aug 9, 2022 (view filing)Aug 54 daysSwayze EricEVP ResearchSSale−1$45.20−$45.20.0%20.4K after
Sep 12, 2022 (view filing)Sep 84 daysSwayze EricEVP ResearchSSale−460$44.55−$20.5K−2.3%19.9K after
Jan 18, 2023 (view filing)Jan 171 dayKlein Joseph IIIDirectorSSale−2.00K$40.00−$80.0K−10.6%16.8K after
Jan 19, 2023 (view filing)Jan 181 dayBaroldi JosephEVP, Chief Business OfficerSSale−375$39.79−$14.9K−30.6%851 after
Jan 19, 2023 (view filing)Jan 181 dayBennett C FrankEVP, Chief Scientific OfficerSSale−6.98K$38.89−$271.4K−9.3%67.9K after
Jan 19, 2023 (view filing)Jan 181 dayCadoret-Manier OnaizaEVP, Chf GL Pdt Str & Oper OfcSSale−3.75K$39.55−$148.2K−16.8%18.5K after
Jan 19, 2023 (view filing)Jan 181 dayGeary Richard SEVP, Chief Development OfficerSSale−7.87K$39.57−$311.5K−10.0%70.5K after
Jan 19, 2023 (view filing)Jan 181 dayHougen Elizabeth LEVP, Finance & CFOSSale−8.28K$39.70−$328.7K−10.1%73.4K after
Jan 19, 2023 (view filing)Jan 181 dayMonia Brett PChief Executive OfficerSSale−25.1K$39.49−$989.9K−17.2%120.9K after
Jan 19, 2023 (view filing)Jan 181 dayO'Neil Patrick R.EVP CLO & General CounselSSale−7.84K$39.49−$309.4K−13.9%48.7K after
Jan 19, 2023 (view filing)Jan 181 daySchneider EugeneEVP, Chf Clinical Develop OfcrSSale−4.75K$39.57−$188.0K−17.5%22.3K after
Jan 19, 2023 (view filing)Jan 181 daySwayze EricEVP ResearchSSale−5.63K$39.74−$223.8K−15.8%30.0K after
Feb 2, 2023 (view filing)Jan 30-313 daysLateO'Neil Patrick R.EVP CLO & General CounselSSale−9.00K$39.57−$356.1K−18.5%39.7K after2 lots
Feb 7, 2023 (view filing)Feb 61 dayBennett C FrankEVP, Chief Scientific OfficerSSale−1.81K$40.57−$73.6K−2.5%69.7K after
Feb 7, 2023 (view filing)Feb 61 dayCadoret-Manier OnaizaEVP, Chf GL Pdt Str & Oper OfcSSale−1.45K$40.66−$59.0K−6.4%21.2K after
Feb 7, 2023 (view filing)Feb 61 dayGeary Richard SEVP, Chief Development OfficerSSale−1.92K$40.66−$78.1K−2.6%72.4K after
Feb 7, 2023 (view filing)Feb 61 dayHougen Elizabeth LEVP, Finance & CFOSSale−2.08K$40.59−$84.4K−2.7%75.5K after
Feb 7, 2023 (view filing)Feb 61 dayMonia Brett PChief Executive OfficerSSale−24.7K$40.69−$1.00M−14.5%145.3K after
Feb 7, 2023 (view filing)Feb 61 dayO'Neil Patrick R.EVP CLO & General CounselSSale−1.92K$40.86−$78.5K−4.4%41.6K after
Feb 7, 2023 (view filing)Feb 61 daySchneider EugeneEVP, Chf Clinical Develop OfcrSSale−1.41K$40.67−$57.5K−5.4%24.9K after
Feb 7, 2023 (view filing)Feb 61 daySwayze EricEVP ResearchSSale−1.81K$40.79−$74.0K−5.4%31.9K after
Apr 19, 2023 (view filing)Apr 181 dayBaroldi JosephEVP, Chief Business OfficerSSale−3.88K$36.50−$141.6K−26.8%10.6K after
Apr 19, 2023 (view filing)Apr 181 dayCadoret-Manier OnaizaEVP, Chf GL Pdt Str & Oper OfcSSale−2.58K$36.50−$94.2K−9.6%24.3K after
Apr 19, 2023 (view filing)Apr 181 dayBirchler BrianEVP, Corp and Development OpsSSale−672$36.50−$24.5K−1.8%36.5K after
May 24, 2023 (view filing)May 222 daysMonia Brett PChief Executive OfficerSSale−4.93K$40.14−$197.9K−3.4%140.4K after2 lots10b5-1
May 24, 2023 (view filing)May 24Same dayO'Neil Patrick R.EVP CLO & General CounselSSale−1.53K$41.70−$63.7K−3.6%40.4K after10b5-1
Jul 11, 2023 (view filing)Jul 74 daysMonia Brett PChief Executive OfficerSSale−18.6K$42.25−$788.0K−13.3%121.7K after10b5-1
Jul 19, 2023 (view filing)Jul 181 dayKlein Joseph IIIDirectorSSale−3.56K$42.00−$149.3K−14.9%20.3K after
Aug 3, 2023 (view filing)Aug 12 daysDiaz Allene M.DirectorSSale−657$41.05−$27.0K−4.9%12.7K after10b5-1
Sep 28, 2023 (view filing)Sep 262 daysKlein Joseph IIIDirectorSSale−2.00K$45.13−$90.3K−9.8%18.3K after10b5-1
Sep 28, 2023 (view filing)Sep 262 daysParshall B LynneDirectorSSale−10.0K$45.13−$451.3K−10.8%82.6K after10b5-1
Sep 29, 2023 (view filing)Sep 281 dayBennett C FrankEVP, Chief Scientific OfficerSSale−4.46K$46.50−$207.4K−6.4%65.8K after10b5-1
Oct 16, 2023 (view filing)Oct 124 daysMonia Brett PChief Executive OfficerSSale−3.77K$46.00−$173.4K−3.1%118.1K after10b5-1
Oct 18, 2023 (view filing)Oct 171 daySwayze EricEVP ResearchSSale−52$47.95−$2.49K−41.6%73 after
Nov 17, 2023 (view filing)Nov 152 daysKlein Joseph IIIDirectorSSale−2.00K$50.00−$100.0K−10.9%16.3K after10b5-1
Dec 18, 2023 (view filing)Dec 144 daysBennett C FrankEVP, Chief Scientific OfficerSSale−22.6K$49.58−$1.12M−25.6%65.8K after2 lots10b5-1
Dec 18, 2023 (view filing)Dec 144 daysGeary Richard SEVP, Chief Development OfficerSSale−10.6K$49.58−$526.2K−12.7%73.0K after2 lots10b5-1
Dec 18, 2023 (view filing)Dec 144 daysMonia Brett PChief Executive OfficerSSale−24.0K$49.58−$1.19M−16.9%118.1K after2 lots10b5-1
Dec 22, 2023 (view filing)Dec 20-212 daysMonia Brett PChief Executive OfficerSSale−24.0K$49.38−$1.19M−16.9%118.1K after2 lots10b5-1
Dec 22, 2023 (view filing)Dec 20-212 daysGeary Richard SEVP, Chief Development OfficerSSale−10.6K$49.50−$525.3K−12.7%73.0K after2 lots10b5-1
Dec 22, 2023 (view filing)Dec 20-212 daysBennett C FrankEVP, Chief Scientific OfficerSSale−22.6K$49.39−$1.12M−25.6%65.8K after2 lots10b5-1
Dec 28, 2023 (view filing)Dec 262 daysSchneider EugeneEVP, Chf Clinical Develop OfcrSSale−25.0K$51.46−$1.29M−40.9%36.1K after10b5-1
Dec 28, 2023 (view filing)Dec 26-282 daysParshall B LynneDirectorSSale−117.6K$50.48−$5.94M−58.8%82.6K after3 lots10b5-1
Dec 28, 2023 (view filing)Dec 262 daysO'Neil Patrick R.EVP CLO & General CounselSSale−20.8K$51.46−$1.07M−34.0%40.4K after10b5-1
Jan 2, 2024 (view filing)Dec 28, 20235 daysSwayze EricEVP ResearchSSale−27.1K$50.19−$1.36M−45.5%32.5K after10b5-1